Graft Versus Host Disease (GVHD) (Immunology) - Drugs In Development, 2021

July 2021 | 842 pages | ID: GCE17FE7D177EN
Global Markets Direct

Abstracts

Graft Versus Host Disease (GVHD) (Immunology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease - Drugs In Development, 2021, provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 8, 37, 21, 6, 48, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 15 and 2 molecules, respectively.

Graft Versus Host Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).
• The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Graft Versus Host Disease (GVHD) - Overview
Graft Versus Host Disease (GVHD) - Therapeutics Development
Graft Versus Host Disease (GVHD) - Therapeutics Assessment
Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
Graft Versus Host Disease (GVHD) - Drug Profiles
Graft Versus Host Disease (GVHD) - Dormant Projects
Graft Versus Host Disease (GVHD) - Discontinued Products
Graft Versus Host Disease (GVHD) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Graft Versus Host Disease (GVHD), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Graft Versus Host Disease (GVHD) - Pipeline by 9 Meters Biopharma Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Abbisko Therapeutics Co Ltd, 2021
Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Accro BioScience (Suzhou) Co Ltd, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Actitrexx GmbH, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech SA, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Agenus Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Alphamab Oncology, 2021
Graft Versus Host Disease (GVHD) - Pipeline by AltruBio Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by AnaMar AB, 2021
Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by ASC Therapeutics Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by AstraZeneca Plc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Athos Therapeutics Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Autolus Therapeutics Plc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Avalon GloboCare Corp, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Biocon Ltd, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by BioIncept LLC, 2021
Graft Versus Host Disease (GVHD) - Pipeline by BioTheryX Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by BlueRock Therapeutics LLC, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Boryung ViGenCell Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Bristol Myers Squibb Co, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biotechnology Ltd, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Cellective BioTherapy Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Cellenkos Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Cellestia Biotech AG, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Cellix Bio Pvt Ltd, 2021
Graft Versus Host Disease (GVHD) - Pipeline by CELLnLIFE Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Celltrion Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Cellvation Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by CheckPoint Immunology Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Claritas Pharmaceuticals Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Kamada Pharmaceuticals, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Kiniksa Pharmaceuticals Ltd, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd, 2021
Graft Versus Host Disease (GVHD) - Pipeline by MaaT Pharma, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Machavert Pharmaceuticals LLC, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Magenta Therapeutics Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Medexus Pharmaceuticals Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Medicenna Therapeutics Corp, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Mediolanum farmaceutici SpA, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Medsenic SAS, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Merck & Co Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Mereo Biopharma Group Plc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by MitoImmune Therapeutics Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by NapaJen Pharma Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Neovii Pharmaceuticals AG, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Nurix Therapeutics Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by OncoC4 Inc, 2021
Graft Versus Host Disease (GVHD) - Pipeline by Orca Biosystems Inc, 2021
Graft Versus Host Disease (GVHD) - Dormant Projects, 2021
Graft Versus Host Disease (GVHD) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Graft Versus Host Disease (GVHD), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021